— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.
— Government contract revenue was $413,458 for the three months ended December 31, 2019.
— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.
— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.
— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.
Most Popular
DRI Earnings: Darden Restaurants’ Q2 2026 sales and profit rise YoY
Darden Restaurants, Inc. (NYSE: DRI), a leading fine dining restaurant chain, on Thursday reported an increase in sales and adjusted earnings for the second quarter of fiscal 2026. Total sales
CarMax (KMX) Q3 2026 earnings drop on lower sales; results beat estimates
Used car retailer CarMax, Inc. (NYSE: KMX) on Thursday reported a decline in earnings for the third quarter of fiscal 2026, hurt by lower sales. However, both revenues and earnings
ACN Earnings: Key quarterly highlights from Accenture’s Q1 2026 financial results
Accenture (NYSE: ACN) reported its first quarter 2026 earnings results today. Revenues of $18.7 billion increased 6% in US dollars and 5% in local currency compared to the same period a
